Illumina Appoints Eli Lilly's Chief Scientific and Product Officer Skovronsky to Board
Illumina appointed Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly and Company, to its board effective June 16, 2026. The appointment brings pharmaceutical industry leadership perspective to the genomics sequencing company's governance.
Illumina appointed Daniel M. Skovronsky to its board of directors effective June 16, 2026 [1]. Skovronsky holds the title of Chief Scientific and Product Officer at Eli Lilly and Company, where he oversees pharmaceutical research and development [1].
The appointment brings pharmaceutical industry perspective to Illumina's board at a time when genomics sequencing is increasingly central to drug discovery and precision medicine. Skovronsky's role at Lilly positions him at the intersection of the two companies' strategic interests: Illumina provides the sequencing platforms that enable genomic research, while Lilly develops therapies informed by that research.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.